NCT04256993View on ClinicalTrials.gov

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

CompletedOBSERVATIONAL
Enrollment

1,434

Participants

Timeline

Start Date

February 15, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.

DRUG

Other standard care

Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.

Trial Locations (1)

Unknown

Database Study, Database Study

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY